Vocabria + Rekambys associated with greater adherence versus daily oral therapy in a US real-world study, as ViiV Healthcare presents broader long-acting portfolio and pipeline data at HIV Glasgow
ViiV Healthcare press release
Findings showcase the real-world effectiveness of long-acting injectable medicines across groups with unmet needs; new pipeline data highlight the potential for twice-yearly HIV treatment.
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
-
[HIV Glasgow 2026] [Press release] Gilead Sciences | New data show twice-yearly lenacapavir achieved nearly twice the one-year persistence of daily oral F/TDF in HIV prevention
-
HIV i-Base | Injectable lenacapavir plus CAB-LA: high viral efficacy but ViiV and Gilead block further research
-
TheBodyPro | Long-acting ART in the real world: New data on efficacy, persistence, and nonsuppression timing
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.